Member Info for Hurst10

Precision talks will be on the agenda.
AVA6000 and 3396 just the start

https://10times.com/e1z4-x9p0-r0fs

Precision & Diagnostics conference 14-15/9 in Chicago

https://www.aacc.org/meetings-and-events/annual-meeting

We now have 20/ bid v 5/ offered, they must be waking up in NY.
Look at the M&A activity in the sector over there!
Not only do we have AVA 6000 etc , but also Affyxell in Korea and the Chinese investing in our JV gene editing / stemcell company.
The investor Genscript Probio comes from Genscript Biotech corp, who also created Legend Biotech. Affyxell fits nicely into the family.
+ AACC next week in Chicago.

Worth remembering that GenScript Probio(new investor in Affylix) is a segment of Genscript Biotech corporation,a global biotech, who also spun off Legend biotech,developing leading drugs with Johnson&Johnson.
Avacta into the premier league!

More print hours prints at premium price.
Gene editing US company up another 8.5%, 145% this month alone.
With recent and upcoming news flow from Genscript Bio,Byocytogen and Affyxelll, it is very we will have a complete rerating of Affyxell and Avacta’s participation.

English version?

Have problem obtaining English version

Verve Therapeutics continues to move higher post BMO upgrade, based on significant long term upside in the Gene editing. The sector is attracting a lot of buying state side.
Stock up another 12% today, +145% this month alone.
Read across to Avacta and Daewoong and Affyxell.
Gene editing and Stemcell DW-MSC technology.
JV’s with GeneScript probio and Biocytogen.
The sector is going through a complete re rating.

50/ bought over the last 17 min.
BEGO on the bid pre US opening
Stand by for more upgrades in Point Biopharma and Verve therapeutics at the opening

US gene therapy and Gene editing companies continues upwards after BMO’s upgrade yesterday, Verve up another 8% today, + 108% in 1M.

Another upgrade in the sector, this time Verve therapeutics with price target increased from $45 to $62.From a valuation point of view,this certainly makes Affyxell’s recent announcement of a partnership with Biocytogen even more interesting and should attract a potential Nasdaq listing.

?

Just to point out the following:
BEGO moved from best offer to best bid, several 5K buy trades going though buy/sell ratio est 80% buy’s.
Novartis earnings conference call later this afternoon, with the company talking much more about gene/radio therapy

From today’s result:
Novartis is a focused medicines company, with depth in five core therapeutic areas (Hematology, Solid Tumors, Immunology, Neuroscience and Cardiovascular), strength in technology platforms (Gene Therapy, Cell Therapy, Radioligand Therapy, Targeted Protein Degradation and xRNA), and a balanced geographic footprint. Our confidence to grow in the near to mid-term is driven by potential multi-billion- dollar sales from our key growth brands: Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. To fuel further growth through 2030 and beyond, we have 20+ assets with significant sales potential that could be approved by 2026.

Note comment ref their technology platform.
Interesting conference call comming up

The Bill & Melinda Gates Foundation revealed a 7.4% stake in LumiraDx (NASDAQ:LMDX), sending shares of the small-cap diagnostics company surging ~23% after hours.
The passive stake was disclosed in a 13G filing with the U.S. SEC on Friday.
London-based LMDX has a partnership with the Bill & Melinda Gates Foundation to distribute its rapid COVID-19 test and its various multi-assay testing platforms to African countries.

Brookline Capital Markets – Newport Biotech Symposium
Management representative: Dr. Joe McCann, Chief Executive Officer
Format: 1x1 meetings
Date: Monday, July 18, 2022
Time: 9:30 am ET – 4:00 pm ET

July 18, 2022 07:00 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--Brookline Capital Markets is hosting the Brookline Capital Markets Biotech Symposium today at the International Tennis Hall of Fame in Newport, Rhode Island. The theme of the meeting is “Transformative Biotech – Cancer, Rare Diseases, and Infectious Diseases.”

Participants include private and publicly traded biotechnology companies and a group of knowledgeable healthcare investors. The agenda includes company presentations in 1:1 and small group meetings along with relevant topical panels. Presenters include senior executives of leading biotechnology companies and key opinion leaders discussing advances in oncology, rare diseases, and infectious diseases.

The Conference reflects Brookline’s focus on the life sciences sector with a particular focus on cutting-edge companies.

4000 and 16000 both at 10